New zonal centrifuges can conveniently process as much as five orders of magnitude (105) greater sample volumes than conventional swinging-bucket rotors. The continuous-sample-flow-with-banding versions may be used in series with ancillary purification procedures. Here we have studied the combined process: absorption and elution of influenza virus with barium sulfate followed by concentration and isopycnic banding of the virus in a buffered sucrose gradient. Kilogram quantities of impurity have been rapidly separated from grams of purified virus, which have been conveniently concentrated several hundred-fold by the purification process. Experimental vaccines made by these procedures are being evaluated.
By using rate-zonal centrifugation followed by isopycnic banding, we previously demonstrated that commercial influenza virus vaccine could be purified an additional 10-fold and that the protective antigens were separated from most of the pyrogens usually found in such partially purified material (14) . To increase the amount of antigen processed with zonal centrifuges, various ancillary procedures for concentrating and purifying the virus were also reported (15) . In parallel with these studies, new continuous-flow zonal centrifuge systems capable of handling much larger volumes have been developed (1) (2) (3) (4) (5) (6) (7) 18) . This paper reports some of our current collaborative results on the application of these systems to large-scale influenza virus purification.
The results demonstrate the utility of the barium sulfate absorption-elution technique (9, 11, 13) Barium sulfate absorption-elution. Prior to zonal centrifugation, virus was concentrated 3.5 times and partially purified by the barium sulfate, absorptionelution procedure modified as follows:
Virus was absorbed from allantoic fluid (pH 7.8 to 8 .0) at 0 to 3 C by the addition of potassium oxalate and dry barium sulfate as shown in Table 1 . The suspension was stirred for 90 min and allowed to stand overnight. Harvesting of the barium sulfate with absorbed virus was done in a 4-liter bowl Sharples continuous-flow centrifuge at 7,000 rev/min with a flow rate of 50 to 80 liters/hr.
Virus was eluted by resuspending the barium sulfate into one-seventh the original volume of fluid having a composition shown in Table 1 . On the following day, the barium sulfate was removed from the resuspended virus at room temperature by centrifugation at 800 X g for 10 min in an International PR-2 centrifuge. The final eluate containing the partially purified virus was adjusted to pH 8 Plant; reference 6) rotors used in a modified Spinco zonal ultracentrifuge.
The second class of rotors concentrated and purified virus by the continuous-flow-with-banding process (1, 5) . The B-IX rotor used here was an experimental prototype and was modified repeatedly during the course of this study, culminating in the present B-XVI rotor (8) . The K-II centrifuge (Fig. 1 ) used for these studies was a prototype air-driven centrifuge designed and constructed at Oak Ridge as a continuous-flow-with-banding zonal centrifuge suitable for large-capacity production ( the B-IX process. Dilutions of material taken from various peak regions of a similar rate-zonal fractionation of 1OX commercial vaccine concentrate were tested for pyrogenicity in rabbits. Table 2 shows that much of the pyrogen is present with the soluble macromolecular impurity, and was separable from the immunizing fraction by the rate-zonal technique. Based on the dilution giving approximately equal pyrogenicity, the purified virus fraction was one-tenth as pyrogenic as the commercial product from which it came. Very little pyrogen was associated with the large particulate impurity of this lot.
Virus from the B-IX purified and virus from the B-IV rate-zonal purified derivative was diluted, inactivated with Formalin, and sterilized by filtration through HA membranes (Millipore Corp.). These vaccines passed all control testing necessary for vaccine production for human use. Table 3 gives a tabular comparison of the original crude allantoic fluid, B-IX and B-IV vaccines, and a standard lOX Sharples concentrate made from the same lot of eggs, as a control. Table 4 This problem has been largely solved by first absorbing the virus from allantoic fluid with BaSO4, followed by elution with citrate solutions. This process is more efficient for separating the virus from large particulate impurities than other methods we have examined (15) , as shown by the rate-zonal sedimentation profile in Fig,  4 . The adsorption and continuous-flow centrifugation steps are complementary, the first removing large particulate material, and the second eliminating soluble impurities.
For production purposes, the K-II centrifuge has now superseded the B-IX and B-XVI. Figure  5 shows the hemagglutinin and optical density profiles for six strains of influenza virus with the use of the combined process and the K-IIB centrifuge. These are representative profiles from commercial production-sized lots, which utilized an average of 15,000 eggs each. These virus pools were diluted and further processed through Formalin inactivation and bacteriological filtration to make monovalent and polyvalent vaccines. Table 5 lists some of the overall yield and purity data for 12 lots of monovalent vaccine. The sources of losses are shown in Table 6 . Table 7 lists mouse potency data for a BaSO4-K-I1 polyvalent vaccine. After the A and B potency tests were made, this vaccine was found to be inadvertently contaminated with a staphylococcus. It was then sterilized by HA membrane filtration. The C and D tests showed that potency was not lost by this process. Figure 6 shows an electron micrograph of an experimental vaccine made with the combined process.
Portions of the K-II virus pools were further purified by rate zonal centrifugation in the B-XV rotor as previously described. The repurified virus, generally recovered in 25% sucrose, usually contained between 1,000 and 2,000 CCA units and 50 to 100 ,ug of protein per optical density unit at 280 m,u in a 1-cm cell. A typical ultravioletabsorption curve for this highly purified material, with and without X-4 scatter correction is given in Fig. 7 . Figure 8 shows immunodiffusion patterns obtained with rabbit antichicken serum in the center well and highly purified vaccine or commercial vaccine in the peripheral wells.
DISCUSSION
Centrifugation in density gradients, which has been customarily performed in swinging buckets with milliliter quantities of sample and centiliter amounts of gradient, has proved most useful in virology and in other areas as an analytical (and small-scale preparative) technique. The B-IV and B-XV batch type zonal rotors, with total volumes of 1.7 liters, utilizing a deciliter or greater sample volume, extends the preparative possibility of zonal techniques by two orders of magnitude. The continuous-flow, isopycnic banding B-IX rotor (total volume, 750 ml) permits optimal processing of liters or tens of liters of sample to add two or even three more orders of magnitude to the volumes conveniently processed. The larger K-IT centrifuge (volume, 3.6 liters), when used sequentially with other purification procedures, has routinely processed more than 150-liter volumes of allantoic fluid per day. To date, 175 K-IT runs have been made with only minor operating problems. This is approximately 1,300 hr at 27,000 rev/min using two instruments. Kilogram quantities of impurity have been rapidly separated from gram quantities of purified virus, which has been conveniently concentrated several hundredfold by the purification process.
We anticipate that some of the losses listed in Table 6 will be brought under better control. For example, the large sampling losses (10%c) for these prototype runs can be diminished. Most of the virus loss in the K-II gradient (11.4%,) was arbitrarily left in the shoulders by selecting out a relatively narrow band centered on the virus peak. Some of the virus lost in the K-II effluent (24.5%) could have been captured by using a higher rotor speed, a slower flow rate, or possibly by a more efficient core design. Likewise, with further study, improved yields (32.9% loss) from the BaSO4 process are anticipated.
The mouse potency ratios listed in Table 7 represent the factor by which a purified vaccine was diluted in excess of the National Institutes of Health reference standard vaccine to confer equal protection (50% survival for challenged mice). A possible explanation for this enhanced potency in mice is that we underestimate the amount of antigen in these highly purified vaccines. This would happen if the purified virus aggregated irreversibly, causing an unequal distribution of the absolute number of virus particles during the serial dilutions used to measure the virus (CCA test). An aggregate of many virus particles may also be no more efficient than a single virus particle in sticking two red cells together. We have electron microscopic evidence for some virus aggregation. The consequences of such aggregation would be that: (i) some loss of antigen during processing is artifactual and does not represent loss of immunizing mass; (ii) the purity is underestimated; (iii) residual toxicity relates to a higher dose than indicated by the CCA test because we underestimate the amount of antigen given. Alternatively, the mouse may respond more efficiently to a highly purified virus vaccine than to an impure preparation.
Light scattering of the purified virus accounts for a large fraction of the observed absorption in the ultraviolet. Since such scattering depends on both the amount of virus present and on the refractive index of the suspending medium, care must be exercised if absorbance data are used as quantitative purity criteria in influenza virus purification in density (and refractive index) gradients. The clinical evaluation of these vaccines, which is now in process, will be reported elsewhere (F. B. Peck, Jr., et al., in preparation).
